Our lead AMPK activator compound:O304
Our clinical focus is on the development O304, a novel AMPK activator compound that is orally available, exhibits favorable pre-clinical pharmacology and toxicology profiles. Phase I clinical studies with O304, approved by the Swedish Medical Products Agency (MPA) have been initiated. We believe that O304 will have beneficial effects in large populations of individuals with various manifestations of metabolic and cardiovascular diseases associated with aging and/or obesity. O304 also exhibits multiple direct and indirect anti-tumour effects. Our first potential indication for O304 is peripheral arterial disease (PAD), which represents a large clinical need, currently with over 200 million individuals affected.